Antitumour Activity of Dehydroxymethylepoxyquinomycin (DHMEQ): a Literature Review
Carcinogenesis research uncovers new pathogenesis links as vulnerable targets of effective antitumour therapies. Among the key mediators of immune response, cell proliferation, cell apoptosis and inflammation is transcription factor NF-κB. Misregulation of an NF-κB-dependent pathway is found in soli...
Saved in:
Main Authors: | K. Umezawa, Sh. Kh. Gantsev, Sh. R. Kzyrgalin, R. S. Yamidanov, R. A. Amirov, E. I. Zhuk |
---|---|
Format: | Article |
Language: | English |
Published: |
Bashkir State Medical University
2021-04-01
|
Series: | Креативная хирургия и онкология |
Subjects: | |
Online Access: | https://www.surgonco.ru/jour/article/view/572 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Importance of Novel Intraperitoneal Therapy of NF-kappa B Inhibitor DHMEQ
by: Sh. Kh. Gantsev, et al.
Published: (2019-04-01) -
Antitumor Activity of Dehydroxymethylepoxychinomycin (DHMEQ) and Cisplatin Combination in a Model of Disseminated Ovarian Cancer
by: Sh. R. Kzyrgalin, et al.
Published: (2023-10-01) -
INHIBITION OF CANCER CELL INVASION AND METASTASIS BY NF-KAPPA-B INHIBITORS (ИНГИБИРОВАНИЕ ИНВАЗИИ РАКОВЫХ КЛЕТОК И МЕТАСТАЗОВ ПРИ ПОМОЩИ ИНГИБИТОРОВ NF-КАППА-B)
by: T. Ukaji, et al.
Published: (2017-02-01) -
THE TRANSCRIPTION FACTOR NF-KB AS A THERAPEUTIC TARGET IN THE TREATMENT OF MALIGNANT TUMORS
by: K. Umezawa, et al.
Published: (2017-01-01) -
Review of Small Molecule Anticancer NF-κB Inhibitors
by: Sh. R. Kzyrgalin, et al.
Published: (2023-07-01)